

1 **Access to medicines for the treatment of chronic diseases**
2 **in Chile: qualitative analysis of perceived patient**
3 **barriers and facilitators in five regions of the country**

4

5 **Short title**

6 **Access to medicines in Chile: qualitative analysis of**
7 **perceived barriers and facilitators**

8

9 **Authors**

10 Carla Castillo Laborde^{1¶}, Isabel Matute^{1*¶}, Ximena Sgombich^{2&}, Daniel Jofré^{2&}

11 ¹ Center for Epidemiology and Health Policy, Faculty of Medicine Clínica Alemana,
12 Universidad del Desarrollo.

13 ² Nous Communication and Strategy.

14

15 * Corresponding Author

16 Isabel Matute

17 E-mail: mimatute@udd.cl

18

19 ¶ These authors contributed equally to this work.

20 & These authors also contributed equally to this work.

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44 **Abstract**

45 Purpose: To know patients' perceptions of barriers and facilitators in access to medicines in
46 general, and those associated with the treatment of three chronic conditions of high
47 prevalence in Chile: diabetes, dyslipidemia and hypertension. Methods: Ten focus groups of
48 patients with these diseases, diagnosed for at least six months and prescribed medication,
49 were included. These were carried out in five regions of Chile: Arica, in the north, Aysén, in
50 the south, and Valparaíso, Metropolitan, and Maule, in the central zone. The criteria for the
51 formation of groups were region, age, health system (public or private) and socioeconomic
52 level (residence commune). Sessions were recorded, transcribed, and analyzed by categories.
53 Results: The experience of access to medicines is determined by the insurance system, the
54 experience of care with public or private providers, and geographical-administrative
55 difference between capital and other regions. Beneficiaries of public sector, despite their
56 greater socioeconomic vulnerability, perceive greater protection in access: access conditions,
57 delivery reliability and adherence to pharmacological treatment are met. The main problem
58 observed is the financing of treatments not covered by the health system. Policyholders in
59 private sector perceive that they have access to medicines of better quality than those
60 provided free of charge by public sector, but raise fears associated with the inability to afford
61 them and distrust in the process, linked to alliances between laboratories and physicians.
62 Public sector beneficiaries value territorial coverage of primary care, which guarantees
63 access in isolated areas. Regarding the type of provider, public sector shows greater capacity
64 for user loyalty, which is expressed in regular visits and follow-up; unlike discontinuous
65 examinations among private sector beneficiaries. Conclusions: Different access conditions

66 both at the territorial level and in the health subsystems are evident. It is necessary to make
67 progress in addressing the problem of access to medicines in a comprehensive manner.

68

69 **Keywords:** barriers; facilitators; access: medicines: segmentation: qualitative: Chile.

70

71 **Introduction**

72 Medications are one of the most widely used therapeutic tools in medicine; therefore,
73 access is a challenge for health systems. Access to health services, and in this case to
74 medicines, is understood as the opportunity for people to reach and obtain the appropriate
75 services in situations of need (1), i.e., it implies a process that goes from the need for a
76 medication, to its use by the patient (2). Access is a multidimensional concept, which includes
77 availability, acceptability and geographic and financial accessibility as its most important
78 dimensions (3,4). In other words, access to medicines implies their availability at a
79 reasonable distance, their acceptance by patients and physicians and the real possibility of
80 financing. These dimensions, as well as multiple barriers and facilitators associated with each
81 of them, were also identified globally by a scope review on medications associated with three
82 chronic conditions of high prevalence (5), finding that the most reported dimension, in
83 countries of all regions and income levels, is affordability, and among the most relevant
84 barriers, the availability of medications, long distances, cost, professional support and
85 cultural aspects (5).

86

87 Despite the therapeutic importance of pharmaceutical drugs, the lack of access to
88 essential medicines, defined as those that meet the priority health care needs of the

89 population, is one of the most serious public health problems globally, affecting one third of
90 the world's population, with consequences for loss of life and deterioration of health (6).

91

92 In Chile, more than 57% of those over 15 years of age consume at least one
93 medication, with paracetamol and acetyl salicylic acid being the most consumed nationwide,
94 followed by losartan, metformin and atorvastatin (7). Of those with a health condition who
95 receive medical care, 7.4% of people report having problems related to the delivery of
96 medications to the health facility or access to them due to their cost (8). Medications represent
97 the most important item of out-of-pocket spending on health (9); in fact, it is estimated that
98 30% of Chileans have stopped buying medications or stopped their treatments because they
99 cannot afford them (10,11).

100

101 In the case of Chile, there is the public subsystem (FONASA beneficiaries), the
102 private one (ISAPRE beneficiaries), and that of the Armed Forces, presenting a marked
103 selection of risks, which leaves FONASA, for the most part, with the most vulnerable and
104 needy population, and ISAPRE with the richest and healthiest population (12). There are
105 vertical programs associated with certain diseases or conditions (13); that is, if we consider
106 the conditions associated with the most consumed pharmaceutical drugs
107 (losartan/hypertension, metformin/diabetes, atorvastatin/dyslipidemia), we can identify
108 explicit guarantees (GES or AUGÉ) of access, opportunity, financial protection and quality
109 for diabetes and hypertension, both for the beneficiaries of FONASA and those of ISAPRE
110 (free delivery in the case of the former, and with a limited copayment established by law for
111 the latter) (14), and we also identify a program called the Pharmacy Fund (FOFAR), for the
112 FONASA beneficiaries, which ensures the availability (and free delivery) of medicines

113 associated precisely with diabetes, hypertension and dyslipidemia in primary health care
114 facilities (15). Thus, the way in which Chileans access their medicines depends, among
115 others, on the subsystem to which they belong and the health condition from which they
116 suffer.

117

118 In the context described above, the present study aimed to know the patients'
119 perceptions of the barriers and facilitators in access to medicines in general, and in particular
120 regarding those associated with the treatment of three chronic conditions of high prevalence:
121 diabetes, dyslipidemia and hypertension.

122

123 **Materials and Methods**

124

125 **Participants and context**

126 Ten focus groups were held between January and March 2021 in 5 regions of Chile:
127 Arica and Parinacota (one) in the north, Aysén (one) in the south, and Valparaíso (one),
128 Metropolitan (five) and Maule (two) in the central area.

129

130 The composition of the groups was defined according to: region, sex (both), age (45-
131 64 and over 65 years), health care system (FONASA and ISAPRE) and socioeconomic level
132 of the municipality of residence (% multidimensional poverty) (16). In addition, the
133 following inclusion criteria were considered: people diagnosed with diabetes, dyslipidemia
134 or hypertension, with prescribed pharmacological treatment, treated in public or private
135 facilities.

136

137 The contact and enrollment process was carried out by a specialized team, identifying
138 the potential participants, who met the profile required for each group, through community
139 networks, delivering an invitation to participate in person, and subsequently re-contacting by
140 phone to answer questions and confirm availability.

141

142 The meetings were held in hotel meeting rooms specifically hired for these purposes
143 and in community centers. All focus groups were in person, so, in consideration of the
144 COVID-19 Pandemic, demanding prevention protocols were observed.

145

146 The focus group participants did so voluntarily and accepted the conditions for
147 carrying out the activity, which was formalized with the signing of an informed consent. This
148 study is part of the FONIS Project SA19|0174, which was approved by the Bioethics
149 Committee of the Faculty of Medicine of Clínica Alemana, Universidad del Desarrollo.

150

151 Each session was recorded and transcribed for further analysis.

152

153 **Data Analysis**

154

155 To address the set objective, three dimensions of inquiry were considered:

156

157 1. General perception of access to health.

158 2. Access to medicines, from five dimensions of access (3–5):

- 159 • Availability: related to the physical existence of medicines,
- 160 • Geographical accessibility: geographical distance between medicines and location
- 161 of users who need them,
- 162 • Affordability: the relationship between the price of medicines and the patients'
- 163 ability to pay,
- 164 • Acceptability: acceptance of medicines by the population or social groups and
- 165 factors that increase or decrease the likelihood of their use; including users'
- 166 attitudes towards suppliers and medicines, and suppliers' attitudes towards user
- 167 characteristics,
- 168 • Adaptation: the relationship between how resources are allocated to deliver
- 169 medicines to users and their ability to adapt.

170

171 3. Access barriers and facilitators. Barriers understood as factors that hinder the target
172 population from obtaining and making appropriate use of the medications it requires; and
173 facilitators as factors that help the target population make use of them.

174

175 The thematic analysis considered an initial stage of familiarization with the data, from
176 the reading of the transcriptions and initial notes. Subsequently, initial categories or codes
177 were established, oriented to the three dimensions mentioned above. A search for topics or
178 reduction of information was carried out based on structuring topics related to the problem
179 investigated. Subsequently, the topics were reviewed, based on a process of re-coding and
180 conceptual delimitation with the support of the Atlas Software.ti 9 (17). Finally, the topics
181 were definitively identified, and a logic tree of topics and subtopics was created.

182

183 Additionally, empathy maps (18) were prepared to outline and characterize types of
184 users in relation to access to medicines, based on the health care subsystem.

185

186 **Results**

187

188 The presentation of the results is divided into three subsections: 1) Description of the
189 participants; 2) General perceptions on access to health, and the barriers and facilitators
190 depending on the dimensions of access (3–5); and 3) the differences between the perceptions
191 of the FONASA and ISAPRE beneficiaries regarding access to medicines.

192

193 **Participant Characteristics**

194

195 In total, for the 10 group interviews, 73 interviewees participated, mostly women
196 (61.6%), FONASA beneficiaries (65.8%), with an average age of 60.2 years. In geographical
197 terms, almost half of those interviewed belonged to the Metropolitan Region, followed by
198 22% in Maule (and rural area), and about 10% in the rest of the regions. Finally, 42.5% of
199 the interviewees resided in communes with a high percentage of multidimensional poverty
200 (Table 1).

201

202

Table 1. Participant Characteristics (n=73)

Average age (min - max)	60.2 (45 - 83)
-------------------------	----------------

Sex	
Female	61.6%
Male	38.4%
Health subsystem	
FONASA (public)	65.8%
ISAPRE (private)	34.2%
Region	
Arica y Parinacota (Arica city)	9.6%
Aysén (Coyhaique city)	9.6%
Maule (Pelarco city)	21.9%
Metropolitan (Cerro Navia, Las Condes, Providencia, San Miguel, Vitacura)	49.3%
Valparaíso (Viña del Mar city)	9.6%
Zone	
Urban	78.1%
Rural	21.9%
Multidimensional poverty in the commune of residence*	
Low (<10%)	27.4%
Medium (>10% and <20%)	30.1%
High (>20%)	42.5%

203

Source Prepared by author.

204

*Based on (16).

205

206 **Access dimensions**

207

208 Below is a summary of the findings on the five access dimensions presented in the
209 previous section (availability, geographical accessibility, affordability, acceptability,
210 adaptation), within which, where possible, they are analyzed in terms of three cross-cutting
211 axes identified as markers of the experience of access to medicines: the insurance system; ii)
212 the experience of care with public and private providers; iii) and the geographical differences
213 (Metropolitan Region/other regions; urban/rural) and other regions.

214

215 **Availability**

216

217 In general terms, for the medicines associated with the three conditions of interest, no
218 stock shortages are identified in the case of FONASA beneficiaries, although sometimes brief
219 delays are observed.

220

221 *“Moderator: Have you been told that the clinic pharmacy has no stock of*
222 *medications?”*

223

All: No.

224

Woman (W): Every month we have a day.

225

Moderator: So how difficult is it for you to access these medications?

226

Man (M): It's easy for me.

227

W: No, it's not difficult.

228

Moderator: And has the current pandemic situation affected access to medicines?

229 *All: No.*

230 *M: On the contrary, it has been become more streamlined.” (FG Arica, mixed,*
231 *FONASA, 45-65 years old)*

232

233 *“W: There are medicines that are sometimes missing, just have to wait*

234 *W: Wait until they arrive, no longer than a week.” (FG Coyhaique, mixed, FONASA,*
235 *45 to 65 years old)*

236

237 However, the scenario changes when it comes to other health conditions that are more
238 complex. In these cases, stock shortages are reported, rarely, which force people to buy in
239 retail pharmacies.

240

241 *“Moderator: So why do you sometimes have to buy them at the pharmacy and not at*
242 *the clinic?*

243 *W: When they do not arrive.*

244 *W: For the problem I have in my spine, I must take an anti-inflammatory, and they*
245 *don't stock it, only Tramadol and Tramadol hurts me, because I have heart*
246 *problems.” (FG Cerro Navia, mixed, FONASA, 45 to 65 years old)*

247

248 **Geographical accessibility**

249

250 In the case of FONASA beneficiaries, the large extension and distribution throughout
251 the national territory of the primary health care network, through which access is preferential,

252 and which was reinforced by the delivery of medicines to homes during the pandemic, is
253 noteworthy.

254

255 *“Moderator: Who had their medications delivered to them during the pandemic?”*

256 *All: I did.*

257 *Moderator: Don Juan, explain a little bit about that, before the pandemic, did they*
258 *deliver medicines or not?*

259 *M: No.*

260 *M: Then, they began to deliver medications during the pandemic, and later in the*
261 *clinic, they said it is a good idea for people over 65 years old.*

262 *W: Until December that happened in my case. I had to go again in January.” (FG*
263 *Coyhaique, mixed, FONASA, 45 to 65 years old)*

264

265 In the case of ISAPRE beneficiaries, access to medicines is preferably through retail
266 pharmacies and, in recent years, through popular pharmacies (which emerged, in 2015, in the
267 municipal context, and which have access to lower prices because they buy through the
268 National Supply Center - CENABAST, like public sector facilities) (19).

269

270 *“M: I buy in pharmacies, but also my wife, who is very much a "go-getter," signed*
271 *up in the Vitacura pharmacy, and there we buy it in the Vitabotica. We buy it at half*
272 *price, less than half price. The truth is super convenient and the other.*

273 *M: Which one?*

274 *W: The Vitabotica.*

275 *M: La Vitabotica". (FG Vitacura – Las Condes, mixed, ISAPRE, 45 to 65 years old)*

276

277 People living in rural areas have some difficulties in accessing their medicines, especially
278 due to periodicity, cost and travel time to clinics.

279

280 *“M: Of course it is complicated for me, because in this time that we are with... last*
281 *week that we were quarantined, many times I could not even come to church, because*
282 *as I say, I am putting a lock on the gate, the bus and collective taxis pass by me,*
283 *because they come full from Talca. I live in a rural area near her, but it's different,*
284 *because she has a car” (FG Pelarco, mixed, FONASA, over 65 years old)*

285

286 The older adults, meanwhile, express and demand the need for prioritized care in
287 retail.

288

289 *“M: From the beginning I wanted to make a clarification, there could be a difference*
290 *in the pharmacies of the older adults, that is, when you go to the pharmacy today,*
291 *there are 20 people in front of you, that is, it is easy to be 45 minutes in a line, and*
292 *more, and I could, at least with an identity card, tell you, Hey, I'm an older adult and*
293 *don't make me wait 45 minutes.” (FG Providencia – Las Condes- San Miguel, mixed,*
294 *ISAPRE, over 65 years old)*

295

296 **Affordability**

297

298 In the case of FONASA beneficiaries, there is recognition and assessment of free
299 access to medicines associated with the three conditions of interest.

300

301 *"Moderator: And have any of you stopped taking medication because you couldn't*
302 *afford it?*

303 *All: No.*

304 *Moderator: And yours is accessible. How much do you spend on diabetes,*
305 *hypertension and cholesterol triglyceride medications?*

306 *M: I don't spend anything*

307 *W: Me neither.*

308 *M: They give us all the medications.*

309 *W: Sure, they give them. (FG Arica, mixed, FONASA, 45 to 65 years old)*

310

311 *"W: Here the one who has money treats the disease he has, and we have to go here*
312 *to the polyclinic that is the closest, and we do not have money to pay the expenses of*
313 *the medicine we need, that's why here in Chile it is bad, very bad "(FG Pelarco,*
314 *mixed, FONASA, 45 to 65 years old)*

315

316 On the other hand, the FONASA user accesses a restricted set of medications
317 (prioritized for coverage) that does not necessarily cover all their health problems. Those
318 health problems whose medicines cannot be afforded are left unattended or partially resolved.
319 This situation is rare when it comes to hypertension, dyslipidemia and diabetes, but it is
320 observed in the management of side effects and in the management of other more complex
321 diseases.

322

323 *W: But later I started to feel well without a problem, but I had to stop buying them if*
324 *I couldn't afford it, a box with 12 pills cost me \$ 57,000. Then I could not do it, it was*
325 *day-to-day that I continued with the polyclinic, but they lowered the dose and healed*
326 *me of my ulcers, and I continue with my medicine from the polyclinic, I will have to*
327 *continue because I do not have the resources to buy a medication of 50 and so*
328 *thousand every month. " (FG Coyhaique, mixed, FONASA, 45 to 65 years old)*

329

330 *"W: I think so, because, because, for example, here in the clinic they tell you*
331 *Metformin and you get Metformin, but if you go to the market, to the pharmacies, it*
332 *is called Hipoglucin, and that medication is so coated that it does not produce the*
333 *effects that Metformin produces.*

334

W: Yes.

335

W: Because of the stomach." (FG Cerro Navia, mixed, FONASA, 45 to 65 years old)

336

337 The GES/AUGE corresponds to a policy that, among others, allows to reduce the
338 economic burden linked to the treatment of diseases such as diabetes and hypertension.
339 Paradoxically, people do not always associate free medicines with this public policy, that is,
340 their direct consequences (availability of medicines) are known but their origin in the GES
341 (or in FOFAR, in the case of dyslipidemia) is not necessarily identified. In practice, this
342 policy is so relevant that the most economically vulnerable groups could not attempt not to
343 have free medicines, at least for hypertension, diabetes and dyslipidemia.

344

345 *"Moderator: Do any of you receive these medicines from GES?"*

346 *W: No, what is that?*

347 *Moderator: Do any of you receive medication through GES?*

348 *Several ask: What is it?*

349 *W: what is GES?" (FG Coyhaique, mixed, FONASA, 45 to 65 years old)*

350

351 In the case of ISAPRE beneficiaries, in general they pay directly for medications for
352 hypertension, diabetes and dyslipidemia, predominating in this group the idea that free access
353 refers to socially vulnerable groups and cared for in the primary health care network, clearly
354 appearing the concept of social class different from their own: "That class is the most
355 vulnerable".

356

357 *"M: I believe that the vast majority buy them.*

358 *W: You just have to buy them.*

359 *M: Out of your pocket.*

360 *M: I think there is a very small class, and that class is the one that is most vulnerable,*
361 *it is the one that resorts to primary health care which are the SAMU, or SAPU, I do*
362 *not know what they are called now.*

363 *M: But most I think still resort to buying them with their money, in a particular way."*

364 *(FG Viña del Mar, mixed, ISAPRE, 45 to 65 years old)*

365

366 For this group of beneficiaries, there is a lack of knowledge and low use of
367 GES/AUGE and the medication coverage it offers; they preferentially choose to maintain
368 freedom of purchase and their relationship with the treating doctors. In ISAPRE the
369 GES/AUGE are attended by a closed network of private providers, defined a priori by each

370 insurer, therefore, they restrict the free choice or continuity of treatment with the treating
371 physician, before having to adapt to the GES protocols (or AUGE). The cost of medicines
372 would be considered marginal relative to meeting the requirements of the plan enrollment.
373 From the perception and beliefs of these users, there is a lack of information and
374 understanding about the process of accessing GES, even some assume that they would have
375 to pertain to the public health care system, which would be a barrier to access for these
376 segments.

377

378 *"Moderator: Have you made use of GES for these pathologies [diabetes,*
379 *hypertension]?"*

380 *W: No.*

381 *W: No.*

382 *W: It is that my apprehension was ultimately, according to what I understand, they*
383 *force you to a doctor from the Auge...*

384 *W: In the ISAPRE.*

385 *W: Sure, and ultimately if you want to go to your doctor, you can't.*

386 *M: Unless it just coincides...*

387 *W: Ah, but that's very difficult.*

388 *W: But what you can do, for example, is go to the doctor from the Auge, to examine*
389 *you, to give you the medicines, which are quite cheap, and then you tell your doctor,*
390 *every so often, you know that they are giving me so much, go check.*

391 *W: Ah, there you have a parallel.*

392 *W: Sure." (FG Vitacura – Las Condes, mixed, ISAPRE, 45 to 65 years old)*

393 In this way, the use of GES, for this group, would be justified in the case of pathologies with
394 higher cost treatments.

395

396 *“M: For the medication I take for the prostate issue, which is another issue, I do it*
397 *through GES.*

398 *W: Oh too.*

399 *W: Ah, but you pay nothing there.*

400 *M: Of course, it is a daily pill, which are 30. They cost \$45,000.*

401 *Moderator: \$45.000?*

402 *M: And if not a little more. And on the other hand, five.*

403 *W: Wow, I mean, I do all the management anyway.*

404 *W: You pay \$5,000 monthly.*

405 *W: What happens is that your pathology was in the GES, in the Auge, so you register,*
406 *that the doctor registers you for the Auge, you call the ISAPRE and the ISAPRE refers*
407 *you to a doctor from the Auge and you must pay that monthly \$ 5,000." (FG Vitacura*
408 *– Las Condes, mixed, ISAPRE, 45 to 65 years old)*

409

410 On the other hand, it is recognized, among this group of users, that GES operates as a
411 conditional transfer, that is, the delivery of medicines requires the person to go through
412 systematic health checkups.

413

414 *“M: Of course, I go every 6 months to the doctor, they examine me, they still do*
415 *exams, they force you to be monitoring, which is a bit the idea, because ultimately*

416 *people let themselves go a bit." (FG Vitacura – Las Condes, mixed, ISAPRE, 45 to 65*
417 *years old)*

418

419 Another element that interferes with people's access to GES coverage is the role
420 played by doctors, who can act as facilitators or hinder access to GES.

421

422 *"W: They do not tell you, there are doctors who do and others who do not, for*
423 *example, I always went to the ophthalmologist and, well, I was going for the driver's*
424 *license that previously took away a year for not wearing glasses, but pretentiously,*
425 *not anymore, so I went to the ophthalmologist, well she happily ... I, exceptional,*
426 *because she told me "you know what, you can come in one more week", Yes, I told*
427 *her, but why "because in five more days you turn 65 and I can give them to you*
428 *through the GES", but because she proposed it to me, because otherwise I would have*
429 *had no idea". (FG Providencia -Las Condes – San Miguel, mixed, ISAPRE, over 65*
430 *years old)*

431

432 In general terms, beyond the differences in terms of the health subsystem to which
433 the beneficiaries belong, and the three chronic conditions of interest (whose medicines they
434 access either free or at low cost), in terms of affordability, the existence of a precarious
435 balance in terms of access to medicines is recognized among the participants. The occurrence
436 of a simple event, such as the emergence of diseases that affect other members of the family
437 group, or other diseases with treatments not covered or of higher cost, is enough to destabilize
438 the family budget, and often force them to prioritize.

439

440 *W: One has a relatively easy time, but it is enough that someone gets sick, I do not*
441 *know, an illness, my daughter needed antibiotics and 50 thousand pesos an antibiotic,*
442 *more, I do not know, other things and the budget, apart from what I am taking fixed*
443 *every month, there is no budget that endures in terms of medicines. Any family can*
444 *be economically destabilized in a month with an illness, in a month. One can*
445 *overcome it, but it is in installments, you get indebted to get out of that and that's how*
446 *it is." (FG Providencia – Las Condes, mixed, FONASA and ISAPRE, 45- 65 years*
447 *old)*

448

449 Finally, from the point of view of affordability, a positive assessment towards Popular
450 Pharmacies is also perceived.

451

452 *W: I will always buy a medicine that is for osteoarthritis that in the pharmacy costs*
453 *about \$ 27,000 and here it costs 16, it is a tremendous, what is it called, savings, and*
454 *there are many people who do not know that type of help.*

455 *W: That's super important and valuable because you save a lot of money that you can*
456 *spend on food or milk, on anything, so...*

457 *W: It has to say permanent prescription and has nothing to do with social class, only*
458 *medication and diagnosis. " (FG Coyhaique, mixed, FONASA, 45 to 65 years old)*

459

460 **Acceptability**

461

462 FONASA beneficiaries, who receive free medicines through the network of public
463 providers, are confident that these will yield benefits for their health, and in some cases the
464 quality is even considered to have improved over time.

465

466 *"Moderator: So, about the quality and effectiveness of the medications you receive in*
467 *the clinic. How do you evaluate them? What do you think of the medications you are*
468 *given?*

469 *M: To me they are good.*

470 *W: Same.*

471 *W: Very good too.*

472 *M: Good because the doctor, although it is true, gives you the prescription and*
473 *everything. It's the exact thing, what's needed, the corresponding doses, everything.*
474 *No problem.*

475 *M: Yes, very good.*

476 *Moderator: And do you think the medications from the clinic could do any harm? Or*
477 *not?*

478 *M: No*

479 *Moderator: Do you trust your medications 100%?*

480 *M: Yes, because it has changed a lot. Before there were quite a few Chilean*
481 *laboratories, but much has changed. The medications have changed." (FG Arica,*
482 *mixed, FONASA, 45 to 65 years old)*

483

484 However, although the effectiveness of medicines for the diseases studied is not
485 questioned, in the case of Metformin the side effects are suffered, which result in additional

486 health expenses to overcome them. This situation is reported in several groups of users served
487 in the public health care network.

488

489 *"W: I already told you, they did X-rays, ultrasound scans, the whole story. What*
490 *happened: consequently, I got ulcers with metformin, apart from the fact that it is a*
491 *very large pill, it is very unpleasant to take it, and you must break it and the whole*
492 *story. Then the doctor told me, he gave me the alternative, unfortunately I cannot give*
493 *you another medication because we are a polyclinic.*

494 *W: Now, I started to take Metformin again, and it makes me vomit and gives me*
495 *diarrhea." (FG Coyhaique, mixed, FONASA, 45 to 65 years old)*

496

497 On the other hand, among the ISAPRE beneficiaries, higher prices are associated with
498 greater effectiveness, perceiving a higher quality of the medicines they buy in retail
499 pharmacies, than those received by FONASA beneficiaries in the public sector. In this sense,
500 belonging to an ISAPRE would be a guarantee of access to medicines that are considered
501 more expensive, but also more effective.

502

503 *"Moderator: Do you think that having ISAPRE or FONASA changes access to*
504 *medicines?*

505 *W: Yes.*

506 *Moderator: Why, how?*

507 *W: Because the doctor, in fact, you see, can give him or herself a greater luxury of*
508 *giving you better qualities medications, of not being in an ISAPRE because, for*
509 *example, you go to the clinic, and they give you the cheapest medications there are...*

510 *W: The generics.*

511 *W: That is, generics, which supposedly they say are not the same quality as*
512 *medications that have a name or a pharmacy, that is, from a better laboratory, I do*
513 *not know, it has always been said. " (FG Providencia – Las Condes – San Miguel,*
514 *ISAPRE, over 65 years old)*

515

516 Finally, ISAPRE users express greater reluctance to use bioequivalent medicines,
517 with suspicion predominating in their discourse about the effectiveness and quality of generic
518 and bioequivalent medications. This articulates some beliefs and opinions based on own
519 experiences of use: that they work like placebos, that doses must be increased to reach the
520 effectiveness of a brand-name drug, that the savings may be less if doses are increased.

521

522 *“W: They are not the same either, one can notice it even in terms of sensations, in the*
523 *basics, paracetamol for headache, you have the generic, the bioequivalent and the*
524 *name brand and with the last two your headache goes away and the other, you have*
525 *to take 3 or 4 pills and in the end what is the generic for if it does not work for you, if*
526 *it doesn't give you the result. You say, I spent two more coins or two less coins, but in*
527 *the end, as I took more, the generic came out more expensive.” (FG Providencia –*
528 *Las Condes, mixed, FONASA and ISAPRE, 45- 65 years old)*

529

530 **Adaptation**

531

532 In general, people served in the public network evaluate that the dynamics of
533 medication provision is in line with their possibilities. Medicine pickup is a regular activity
534 that people carry out every month and that keeps them in contact with the health care system.
535 The extensive territorial network of health facilities addresses the issue of physical distance
536 being accessible to users.

537

538 *“Moderator: And how often, how many times... How often do you actually go to the*
539 *clinic to get your medication?”*

540 *W: Every month.*

541 *M: Each month.*

542 *W: Every month.*

543 *W: Every month we have a day.*

544 *Moderator: So how difficult is it for you to access these medications?*

545 *M: It's easy for me.*

546 *W: No, it's not difficult.” (FG Arica, mixed, FONASA, 45 to 65 years old)*

547

548 The logistics of medicine provision is one of the most recognized aspects of primary
549 care; there are significant improvements in terms of access and treatment, and it introduces
550 a differentiation between public clinics and hospitals, where the latter represent the most
551 critical face of the public health system.

552

553 The adaptation is lower in very particular cases that are referred to groups, such as
554 people who live alone and have lost autonomy, older adults with disabilities or people living
555 in isolated places, these segments can evaluate their access possibilities as restricted.

556

557 *“M: But in general, the great majority of people are very few who are isolated, very*
558 *few, the great majority have good services.” (FG Coyhaique, mixed, FONASA, 45 to*
559 *65 years old)*

560

561 *“W: One has to remember to go to pick up the medications, if not, he or she loses*
562 *them, that's where I tell him about the elderly, let's say, there are old people who are*
563 *not... they are old, and they cannot come to pick them up, they have no young person*
564 *to send” (FG Pelarco, FONASA, 45 to 65 years old)*

565

566 **FONASA and ISAPRE differences**

567

568 Figures 1 and 2 present the empathy maps associated with the FONASA and ISAPRE
569 beneficiaries, respectively.

570

571 According to that presented in Figure 1, it is possible to note that FONASA
572 beneficiaries, despite their greater socio-economic vulnerability, perceive greater protection
573 in access to their medicines. Access conditions, delivery regularity and adherence to
574 pharmacological treatment are met. For this group, the treatment financing for comorbidities
575 and morbidities of the family group is perceived as the main problem.

576

577 **Figure 1. FONASA Beneficiary Empathy Map**

578

579 On the other hand, users in the public sector value the territorial coverage of primary
580 care, which guarantees access in isolated areas. Regarding the type of provider, the public
581 sector shows greater capacity for loyalty of users, which is expressed in regular check-ups
582 and feeling of monitoring; unlike more irregular visits among beneficiaries of the private
583 sector.

584

585 As observed in Figure 2, private sector policyholders, for their part, understand that
586 they have access to better quality medicines than those provided free of charge by the public
587 sector. However, they report fears associated with inability to afford them and greater distrust
588 in the process, linked to alliances between laboratories and physicians.

589

590 **Figure 2. ISAPRE Beneficiary Empathy Map**

591

592 **Discussion**

593

594 The findings of the present study characterize the access to medicines in Chile of
595 people of different socioeconomic conditions and residents in scattered regions of the
596 country, for the three chronic conditions of interest: hypertension, diabetes and dyslipidemia.

597 As mentioned in the introductory section, these three non-communicable conditions have a
598 high prevalence in Chile and, from the point of view of coverage by the health system, they
599 have been prioritized, through the Explicit Health Guarantees – GES, for the FONASA and
600 ISAPRE beneficiaries, and the Primary Health Care Pharmacy Fund, for the FONASA
601 beneficiaries (20).

602

603 The high segmentation of the Chilean health system, the geographical extension of
604 the country, as well as the existence of rural and isolated areas throughout the territory
605 significantly determine the way Chileans access their medicines, as well as the barriers they
606 must face, and the facilitators they have in the process.

607

608 The provision of medicines is affected by variables in the organization of health
609 services. It is noteworthy that primary care has succeeded in establishing coordination and
610 monitoring of the population caring for, at least for chronic diseases, which would favor the
611 control of these diseases.

612

613 The above explains that, in general terms, people affiliated with FONASA have
614 access to medicines for the treatment of the diagnoses studied through the institutional public
615 health network, free of charge because of public policies that include: Explicit Health
616 Guarantees (GES or AUGE) and Pharmacy Fund (FOFAR). For their part, the people
617 affiliated with ISAPRE mostly access medications through direct purchase in pharmacies and
618 pay for the entire treatment, which is considered an insignificant expense due to the low cost
619 of these in the case of the three conditions studied. This segment can also access the GES;
620 however, a marginal use of guarantees was observed associated with administrative barriers,
621 ignorance and resistance to attend the preferential network of ISAPRE for the GES, which
622 implies changing the treating physician.

623

624 In general terms, there are no relevant barriers in the case of medicines for the three
625 conditions of interest for FONASA beneficiaries. However, access barriers for other

626 medications are identified and these are associated, in the case of public sector beneficiaries,
627 with out-of-pocket spending on medicines not covered or not prioritized by the health system
628 and, in those cases where the medicines are covered but circumstantially encounter stock
629 shortages in public establishments, the availability barrier appears, with the consequent
630 affordability problems associated with having to purchase them in retail. The facilitators, for
631 their part, include policies and programs that establish medication coverage and guarantee
632 availability and financial protection; the territorial deployment of primary care in the country;
633 and the acceptance and assessment by FONASA users of the public sector care model, which
634 determines the control and permanent contact of users with the health system.

635

636 In the case of private sector beneficiaries who, as mentioned, buy mainly in retail,
637 significantly associating the price of quality medications; one of the barriers identified is
638 adaptation, and has to do with the non-acceptance or rejection by users of retail practices
639 (lack of transparency, collusion, etc.), which in turn is related to the out-of-pocket expenses
640 they must incur. In the case of these beneficiaries, another adaptation barrier also emerges,
641 associated with the lack of knowledge of the processes for obtaining the benefits delivered
642 by the GES, and another of acceptability, related to the rejection of the conditions imposed
643 for obtaining them (e.g., bureaucracy, renunciation of free choice, use of generics). Among
644 the facilitators for the ISAPRE users, there is the budget availability that, in general, allows
645 them to pay for the required medicines, at least for the three chronic conditions of interest for
646 the analysis, the potential lower out-of-pocket expenditure to be able to access through the
647 GES, and the possibility of having complementary coverage through voluntary insurance.

648

649 It is worth mentioning that the eruption of popular or municipal pharmacies is an
650 access facilitator recognized by users in a transversal way, allowing access to lower prices
651 compared to retail.

652

653 The results presented here are in line with findings published in the literature, first,
654 regarding the relevance, as a facilitator for access to medicines, of having coverage or health
655 insurance, from the point of view of out-of-pocket spending and affordability, and as a barrier
656 if this possibility is not available. It is possible to find experiences of countries in different
657 economic or geographical contexts in this regard (21–24). In fact, in the Americas region,
658 there are close examples, such as the case of Brazil with the free delivery of medications by
659 the SUS, and its Health Has no Price programs (for hypertension and diabetes as is of interest
660 in this research) and Popular Pharmacies (25–28). Another barrier that emerges in the study
661 and is also reported in the literature for various countries, such as Barbados, the US and
662 Colombia, relates to the bureaucracy or how complex and cumbersome it is to understand
663 the insurance requirements to obtain medication coverage (29–31), as happens in Chile to the
664 ISAPRE beneficiaries for the use of GES.

665

666 One of the main limitations of this study is related to the conduct of group interviews
667 during the Covid-19 pandemic, which, among others, required strict monitoring of protocols,
668 and also made it necessary to address, within the framework of the interviews, some issues
669 related to access to medication during the pandemic, and then further examine (removing the
670 focus of the pandemic) more general issues associated with this access. However, this
671 limitation became, in turn, an opportunity to explore people's perceptions about access to

672 medicines in the pandemic context, and the ways in which the Chilean health system
673 addressed this problem in this period of greatest difficulties.

674

675 Finally, within the framework of this research it was possible to identify opportunities
676 for improvement for public health policy, among the main ones, and in line with the
677 aforementioned, is the importance of moving towards comprehensive medicine coverage, as
678 well as its free delivery by health systems to achieve better and more equitable access.
679 Another implication relates to the need to strengthen, on the part of the health authority, the
680 messages around the quality of bioequivalents, to increase the confidence of users in the
681 policies of access to generics, which are delivered free of charge by the system. Finally, it is
682 necessary to inform the population about how to access the benefits of policies or programs,
683 and to make the relationship between gratuity and these policies transparent, as part of the
684 State's commitment to advancing the rights of access to health.

685

686 **Acknowledgements**

687

688 The authors thank the financing of the FONIS SA19|0174 Project, granted by the
689 National Agency for Research and Development, Chile (ANID), in the framework of which
690 this study was carried out.

691

692 The authors also thank the fieldwork team for their support in conducting the
693 interviews.

694

695 Finally, we thank all the participants in the interviews conducted for sharing their
696 time and experiences.

697

698 **References**

- 699 1. Levesque J-F, Harris M, Russell G. Patient-centred access to health care:
700 conceptualising access at the interface of health systems and populations. *Int J*
701 *Equity Health*. 2013;12(18):1–9.
- 702 2. Koh JJK, Cheng RX, Yap Y, Haldane V, Tan YG, Teo KWQ, et al. Access and
703 adherence to medications for the primary and secondary prevention of
704 atherosclerotic cardiovascular disease in singapore: A qualitative study. *Patient*
705 *Prefer Adherence*. 2018;12:2481–98.
- 706 3. Tanahashi T. Health service coverage and its evaluation. *Bull World Health Organ*.
707 1978;56(2):295–303.
- 708 4. Penchansky R, Thomas JW. The Concept of Access : Definition and Relationship to
709 Consumer Satisfaction. *Med Care*. 1981;19(2):127–40.
- 710 5. Castillo-Laborde C, Hirmas-Adauy M, Matute I, Jasmén A, Urrejola O, Molina X, et
711 al. Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia
712 Medicines: A Scoping Review. *Public Health Rev*. 2022;43(September):1–18.
- 713 6. Organización Mundial de la Salud. Acceso equitativo a los medicamentos esenciales:
714 un marco para la acción colectiva. 2004.
- 715 7. Ministerio de Salud. Encuesta Nacional de Salud 2016-2017. Uso de medicamentos.
716 2018.
- 717 8. Ministerio de Desarrollo Social. Salud. Síntesis de Resultados Encuesta CASEN

- 718 2017 [Internet]. 2018. Available from:
719 <http://observatorio.ministeriodesarrollosocial.gob.cl/casen->
720 [multidimensional/casen/docs/Resultados_Salud_casen_2017.pdf](http://observatorio.ministeriodesarrollosocial.gob.cl/casen-multidimensional/casen/docs/Resultados_Salud_casen_2017.pdf)
- 721 9. Bruzzo S, Henríquez J, Velasco C. Radiografía del gasto de bolsillo en salud en
722 Chile: una mirada desagregada. Vol. 478, Puntos de Referencia, Centro de Estudios
723 Públicos. 2018.
- 724 10. Ministerio de Salud. Encuesta uso racional de medicamentos. Informe Final. 2011.
- 725 11. Universidad San Sebastián. Encuesta Consumo de Medicamentos. 2017.
- 726 12. Castillo-Laborde C, Aguilera-Sanhueza X, Hirmas-Adaury M, Matute I, Delgado-
727 Becerra I, Ferrari MN-D, et al. Health Insurance Scheme Performance and Effects on
728 Health and Health Inequalities in Chile. *MEDICC Rev.* 2017;19:57–64.
- 729 13. Castillo-Laborde C, Matute Willemsen I, Aguilera-Sanhueza X. Introducción. In:
730 Castillo-Laborde C, Matute Willemsen I, Aguilera-Sanhueza X, editors. *La Ruta del*
731 *Medicamento en Chile.* 2022. p. 15–23.
- 732 14. Ministerio de Salud. Ley 19966. Establece un Régimen de Garantías Explícitas.
733 2004.
- 734 15. Ministerio de Salud. Fondo de Farmacia. FOFAR. [Internet]. 2018 [cited 2018 Dec
735 17]. Available from: <https://www.minsal.cl/fofar/>
- 736 16. Ministerio de Desarrollo Social y Familia. Estimaciones de Tasas de Pobreza por
737 ingresos y Multidimensional por Comunas [Internet]. Observatorio Social; 2017.
738 Available from:
739 <http://observatorio.ministeriodesarrollosocial.gob.cl/storage/docs/pobreza->
740 [comunal/2017/PLANILLA_Estimaciones_comunales_tasa_pobreza_por_ingresos_](http://observatorio.ministeriodesarrollosocial.gob.cl/storage/docs/pobreza-comunal/2017/PLANILLA_Estimaciones_comunales_tasa_pobreza_por_ingresos_multidimensional_2017.xlsx)
741 [multidimensional_2017.xlsx](http://observatorio.ministeriodesarrollosocial.gob.cl/storage/docs/pobreza-comunal/2017/PLANILLA_Estimaciones_comunales_tasa_pobreza_por_ingresos_multidimensional_2017.xlsx)

- 742 17. ATLAS.ti Scientific Software Development GmbH. Atlas.ti. Version 9.1.2. 2021.
- 743 18. Iglesias Y. El Mapa de Empatía [Internet]. 2017 [cited 2022 Apr 18]. Available
744 from: <https://designthinking.gal/el-mapa-de-empatia/>
- 745 19. Ministerio de Salud. Recomendaciones para Farmacias Populares: Orientaciones en
746 Abastecimiento, Vinculación con la Atención Primaria en Salud y Uso Racional de
747 Medicamentos [Internet]. Santiago, Chile; 2018. Available from:
748 [https://www.minsal.cl/wp-content/uploads/2015/09/Recomendaciones-Farmacias-](https://www.minsal.cl/wp-content/uploads/2015/09/Recomendaciones-Farmacias-Populares.pdf)
749 [Populares.pdf](https://www.minsal.cl/wp-content/uploads/2015/09/Recomendaciones-Farmacias-Populares.pdf)
- 750 20. Hirmas Aduy M, Awad Avendaño C. Modalidades de acceso a los medicamentos
751 por parte de los pacientes. In: Castillo-Laborde C, Matute-Willemsen I, Aguilera-
752 Sanhueza X, editors. La Ruta del Medicamento en Chile. 2022. p. 1–114.
- 753 21. Tjia J, JS S. Will the Medicare prescription drug benefit eliminate cost barriers for
754 older adults with diabetes mellitus? *J Am Geriatr Soc* [Internet]. 2006
755 Apr;54(4):606–12. Available from:
756 <http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=106314266&lang>
757 [=es](http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=106314266&lang)
- 758 22. Vialle-Valentin CE, Serumaga B, Wagner AK, Ross-Degnan D. Evidence on access
759 to medicines for chronic diseases from household surveys in five low- and middle-
760 income countries. *Health Policy Plan*. 2015;30(8):1044–52.
- 761 23. Beran D. The Impact of Health Systems on Diabetes Care in Low and Lower Middle
762 Income Countries. *Curr Diab Rep* [Internet]. 2015 Apr 28;15(4):20. Available from:
763 <http://link.springer.com/10.1007/s11892-015-0591-8>
- 764 24. Naheed A, Haldane V, Jafar TH, Chakma N, Legido-Quigley H. Patient pathways
765 and perceptions of hypertension treatment, management, and control in rural

- 766 Bangladesh: a qualitative study. Patient Prefer Adherence [Internet]. 2018
767 Aug;Volume 12:1437–49. Available from: [https://www.dovepress.com/patient-](https://www.dovepress.com/patient-pathways-and-perceptions-of-hypertension-treatment-management--peer-reviewed-article-PPA)
768 [pathways-and-perceptions-of-hypertension-treatment-management--peer-reviewed-](https://www.dovepress.com/patient-pathways-and-perceptions-of-hypertension-treatment-management--peer-reviewed-article-PPA)
769 [article-PPA](https://www.dovepress.com/patient-pathways-and-perceptions-of-hypertension-treatment-management--peer-reviewed-article-PPA)
- 770 25. Araujo JLO, Pereira MD, de Sá Del Fiol F, Barberato-Filho S. Access to
771 Antihypertensive Agents in Brazil: Evaluation of the “Health Has No Price”
772 Program. Clin Ther [Internet]. 2014 Aug;36(8):1191–5. Available from:
773 <https://linkinghub.elsevier.com/retrieve/pii/S0149291814003592>
- 774 26. Araujo JLO, Pereira MD, de Cássia Bergamaschi C, de Sá Del Fiol F, Lopes LC, de
775 Toledo MI, et al. Access to medicines for diabetes treatment in Brazil: evaluation of
776 “health has no price” program. Diabetol Metab Syndr [Internet]. 2016 Dec
777 10;8(1):35. Available from:
778 <http://dmsjournal.biomedcentral.com/articles/10.1186/s13098-016-0150-8>
- 779 27. Emmerick ICM, Campos MR, Luiza VL, Chaves LA, Bertoldi AD, Ross-Degnan D.
780 Retrospective interrupted time series examining hypertension and diabetes medicines
781 usage following changes in patient cost sharing in the “Farmácia Popular”
782 programme in Brazil. BMJ Open [Internet]. 2017 Nov 3;7(11):e017308. Available
783 from: <https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2017-017308>
- 784 28. Fritzen JS, Motter FR, Paniz VMV. Regular access and adherence to medications of
785 the specialized component of pharmaceutical services. Rev Saude Publica [Internet].
786 2017 Nov 27;51:109. Available from:
787 <https://www.revistas.usp.br/rsp/article/view/140988>
- 788 29. Legido-Quigley H, Camacho Lopez PA, Balabanova D, Perel P, Lopez-Jaramillo P,
789 Nieuwlaat R, et al. Patients’ Knowledge, Attitudes, Behaviour and Health Care

- 790 Experiences on the Prevention, Detection, Management and Control of Hypertension
791 in Colombia: A Qualitative Study. Barengo NC, editor. PLoS One [Internet]. 2015
792 Apr 24;10(4):e0122112. Available from:
793 <https://dx.plos.org/10.1371/journal.pone.0122112>
- 794 30. Adams OP, Carter AO. Diabetes and hypertension guidelines and the primary health
795 care practitioner in Barbados: knowledge, attitudes, practices and barriers--a focus
796 group study. BMC Fam Pract [Internet]. 2010 Jan;11:9p–9p. Available from:
797 <http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=105003843&lang>
798 =es
- 799 31. Suraci C, Mulas F, Rossi MC, Gentile S, Giorda CB. Management of newly
800 diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A
801 SUBITO!AMD survey on the early diabetes treatment in Italy. Acta Diabetol.
802 2012;49(6):429–33.
803

Figure 1. FONASA Beneficiary Empathy Map




Figure 2. ISAPRE Beneficiary Empathy Map

